Sign In
Buy TXG
$31.75
-0.470 (-1.46%)
At Close: Jun 16, 2026
SAN CARLOS, Calif.--(BUSINESS WIRE)--LiquidCell Dx, a precision diagnostics company building a blood-based platform for tumor microenvironment profiling, today announced the appointment of Mirna Jaros
10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced
10:21am, Monday, 20'th Apr 2026
TXG stock jumps after unveiling Atera, a next-gen spatial biology platform aiming to scale single-cell analysis and deepen its role in drug discovery and research.
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
10:00pm, Saturday, 18'th Apr 2026
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale Debuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the
Analyzing Hinge Health (NYSE:HNGE) and 10x Genomics (NASDAQ:TXG)
01:11am, Thursday, 16'th Apr 2026
Hinge Health (NYSE: HNGE - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two companies bas
10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026
04:05pm, Wednesday, 15'th Apr 2026
PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended
Comparing 10x Genomics (NASDAQ:TXG) and HeartSciences (NASDAQ:HSCS)
01:58am, Friday, 10'th Apr 2026
10x Genomics (NASDAQ: TXG - Get Free Report) and HeartSciences (NASDAQ: HSCS - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based
Aaron Wealth Advisors LLC Has $1.08 Million Stock Holdings in 10x Genomics $TXG
03:38am, Wednesday, 08'th Apr 2026
Aaron Wealth Advisors LLC raised its holdings in 10x Genomics (NASDAQ: TXG) by 68.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Th
10x Genomics (NASDAQ:TXG) Shares Gap Up on Analyst Upgrade
01:30am, Wednesday, 01'st Apr 2026
Shares of 10x Genomics (NASDAQ: TXG - Get Free Report) gapped up prior to trading on Tuesday after William Blair upgraded the stock from a market perform rating to an outperform rating. The stock had
10x Genomics Seen As Key Player In AI-Driven Biological Data Buildout
02:10pm, Tuesday, 31'st Mar 2026
• 10x Genomics shares are powering higher. What's fueling TXG momentum?
10x Genomics (NASDAQ:TXG) Given Consensus Recommendation of “Hold” by Brokerages
02:29am, Thursday, 26'th Mar 2026
10x Genomics (NASDAQ: TXG - Get Free Report) has earned a consensus recommendation of "Hold" from the sixteen ratings firms that are currently covering the company, MarketBeat reports. Three research
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:52am, Wednesday, 25'th Mar 2026
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way f
The global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world to
10x Genomics: Undervalued Amid Consumables-Led Transition
01:35am, Tuesday, 24'th Mar 2026
10x Genomics is undervalued, with a BUY rating and 18% upside to a $20.47 target, driven by robust consumables growth. Consumables, comprising 83% of revenue, continue double-digit growth, offsetting
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
07:07am, Monday, 23'rd Mar 2026
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's hi
Reviewing Hims & Hers Health (NYSE:HIMS) & 10x Genomics (NASDAQ:TXG)
02:56am, Monday, 23'rd Mar 2026
10x Genomics (NASDAQ: TXG - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both mid-cap medical companies, but which is the better business? We will compare the two compa
